BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN®
June 24 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:
BIOMARIN PRESENTS FIVE-YEAR PHASE 3 RESULTS REINFORCING LONG-TERM EFFICACY AND SAFETY OF ROCTAVIAN® (VALOCTOCOGENE ROXAPARVOVEC-RVOX) AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS 2025 CONGRESS
BIOMARIN PHARMACEUTICAL INC - NO NEW SAFETY SIGNALS OBSERVED IN 5-YEAR ROCTAVIAN STUDY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey








